Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting

Table 1 Immunotherapy in soft tissue sarcoma – results from the 2017 ASCO Annual Meeting

Study	Regimen	Patients evaluable for response	ORR^a	Complete response (histology)	Partial response (histology)	Stable disease	Progressive disease	Median duration of response (weeks)
Burgess et al. [14]	P, 200 mg i.v., Q3 weeks	STS: 40	STS: 18%	1 (UPS)	6 (3 UPS, 2 DDLPS, 1 SS)	15	18	33
Burgess et al. [14]	P, 200 mg i.v., Q3 weeks	BS: 40	BS: 5%	0	2 (1 OS, 1 CS)	9	29	43
Toulmonde et al. [15]	P, 200 mg i.v., Q3 weeks; oral cyclophosphamide 50 mg alternative weeks	50	2%	0	1 (NA)	NA	NA	NA
D’Angelo et al. [13]	N, 3 mg/kg, Q2 weeks	N: 38	N: 5%	0	3 (ASPS, LMS, sarcoma NOS)	15	20	NA
D’Angelo et al. [13]	N, 3 mg/kg, Q3 weeks for 4 cycles, then Q2 weeks; I: 1 mg/kg Q3 weeks for 4 cycles	N + I: 38	N + I: 16%	2 (MFS, uterine LMS)	4 (3 UPS, LMS, angiosarcoma)	19	10	NA
Somaiah et al. [18]	CMB305 regimen (LV305 i.d. injections alternating with G305 i.m. injections for 3 months, then bimonthly G305 injections up to 1 year)	25	0	0	0	16	9	NA

ASPS alveolar soft part sarcoma, BS bone sarcoma, CS chondrosarcoma, I ipilimumab, DDLPS dedifferentiated liposarcoma, LMS leiomyosarcoma, MFS myxofibrosarcoma, N nivolumab, NA not available, NOS not otherwise specified, ORR overall response rate, OS osteosarcoma, P pembrolizumab, SS synovial sarcoma, STS soft tissue sarcoma, UPS undifferentiated pleomorphic sarcoma
^aRECIST 1.1

ISSN: 1741-7015